Human immunodeficiency virus type 1 (HIV-1) establishes a persistent infection that leads to acquired immunodeficiency syndrome (AIDS). Approximately 36 million people worldwide are living with HIV-1, which is commonly acquired through sexual contact. Antiviral therapies control disease progression, but do not eliminate this virus from the host. Thus, global efforts are focused on developing vaccines that prevent HIV-1 transmission. Such vaccines are based on eliciting the production of protective antibodies that target the envelope glycoproteins (Envs) of this virus. Unfortunately, HIV-1 immunization trials have shown limited efficacy. A better understanding of the antibody-mediated inactivation process is needed to improve vaccine strategies. In this work we describe two novel factors that contribute to HIV-1 inactivation. First, we show that structural stability of the Env protein determines its sensitivity to vaccine-elicited antibodies. Different interactions within Env contribute to its stability. Perturbation of the Env-stabilizing interactions by physical and chemical treatments enhances sensitivity of HIV-1 to antibodies. Second, we found that the chemical composition of the transmission medium affects Env inhibition by antibodies and other inhibitory agents. Semen is the most common vehicle for HIV-1 transmission. This medium contains high concentrations of the sugar fructose. We found that semen fructose competitively blocks binding of antiviral agents that target sugar residues on Env. Together, this work advances our understanding of the mechanism that underlies HIV-1 inactivation by vaccine-elicited antibodies and provides novel strategies to enhance their potency.

GB virus C (GBV-C) is a nonpathogenic lymphotropic virus that replicates in B and T lymphocytes. Infection with GBV-C is documented worldwide and is common: between 1% and 5% of healthy blood donors are viremic at the time of donation. Antibodies to GBV-C proteins are not usually detected during viremia, and antibodies to the GBV-C envelope glycoprotein E2 develop following the clearance of viremia. Although GBV-C viremia may persist for decades, viremia usually clears within 2 years following infection in the majority of individuals infected by blood transfusion. A chimpanzee variant of GBV-C, designated GBV-Ccpz, is found in captive and noncaptive chimpanzees and its prevalence and natural history are uncharacterized. GBV-C research was initially performed by viral hepatitis research groups because it was predicted to cause hepatitis. The realization that GBV-C did not cause hepatitis resulted in a marked reduction in research activity. Because Hepatitis C virus co-infection worsens the clinical course of HIV-infected patients, researchers hypothesized that the related virus, GBV-C, may impact HIV disease. In 1998, researchers found that HIV-infected individuals who were co-infected with GBV-C survived longer than those without GBV-C. These findings provide the rationale for examining the relationship of GBV-C and HIV and the development of GBV-C as a novel therapeutic for HIV. GBV-C infection of PBMCs inhibits the replication of HIV isolates and one of the mechanisms for this is the induction of the release of soluble ligands for HIV entry receptors (RANTES, macrophage inflammatory proteins (MIP)-1α and MIP-1β and SDF-1) by GBV-C. The GBV-C envelope glycoprotein E2 contributes directly to the inhibition of HIV infection. Incubation of recombinant E2 with PBMCs at 4°C prior to HIV infection results in a decrease in HIV replication, and only HIV gp160 enveloped pseudoparticle transduction, not VSV-G enveloped pseudoparticle transduction, is inhibited by GBV-C E2. This suggests that GBV-C E2 inhibits HIV infection at an entry step when the HIV gp160 envelope protein interacts with cellular receptors and membranes. How GBV-C E2 interacts with cellular surfaces and which cellular proteins are utilized for GBV-C binding and entry are unknown. Here, we characterize GBV-C E2 binding to human PBMCs, murine cells, and multiple transformed cell lines to identify the PBMC subset which E2 binds and to identify candidate cellular receptors involved in GBV-C binding and entry. Understanding how GBV-C E2 interacts with cellular surfaces is critical to determining how it inhibits HIV entry. Anti-GBV-C E2 antibodies are also associated with improved survival in HIV-infected individuals. Recent studies demonstrated that anti-E2 antibodies neutralize HIV infection in vitro and immunoprecipitate HIV virions. In these studies, we describe how anti-E2 antibodies immunoprecipitate retroviral particles regardless of the specific viral envelope protein on the surface, but only neutralize particles bearing the HIV gp160 envelope protein. We also found that the cellular antigen recognized by anti-E2 antibodies is accessible only in permeabilized cells and not on the cell surface. These studies provide insight into the HIV-inhibitory mechanisms of anti-E2 antibodies, which should aid in the development of GBV-C E2 as an immunogen in an HIV vaccine. Finally, no animal models exist for studying GBV-C infection or GBV-C vaccines as HIV therapeutics in vivo. We examined the natural history GBV-Ccpz in a captive chimpanzee population, and found that the prevalence of GBV-Ccpz viremia and anti-E2 antibodies, as well as the length of persistent infection, were similar to those found in healthy human blood donors. The GBV-Ccpz 5#8217;ntr and RdRp sequences from chimpanzee subspecies troglodytes and verus shared a high level of sequence identity and indicate that the chimpanzee variant should be designated GBV-Ccpz rather than the currently used GBV-Ctrog. These findings demonstrate that GBV-Ccpz viremia and E2 antibody status should be tested in animals involved in clinical research trials because affected animals may have altered responses to GBV-C infection or HIV vaccines, and that the chimpanzee would be a good animal model in which to study GBV-C infection.

Macrophages are target cells for human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) infection that serve as viral reservoirs in brain, lung, gut, and other tissues, and play important roles in disease pathogenesis, particularly HIV/SIV-associated neurological disease. Macrophages express low levels of the HIV/SIV receptor CD4, but mechanisms by which macrophage-tropic viruses use low CD4 to mediate spreading infections are poorly understood. One mechanism involves enhanced envelope glycoprotein (Env) interaction with CD4 or CCR5, but this phenotype is frequently associated with increased neutralization sensitivity to antibodies targeting CD4/CCR5 binding sites. Moreover, this mechanism does not explain how these neutralization-sensitive viruses evade immune responses while establishing spreading infections. In this dissertation, we sought to identify SIV Env determinants for macrophage tropism and characterize mechanisms by which they enhance virus replication in macrophages. To identify viral variants capable of inducing macrophage-associated pathogenesis, we cloned Env sequences from SIV-infected macaques at early and late stage infection, and identified an early variant in blood that shares >98% sequence identity with the consensus sequence of late variants in brain from macaques with neurological disease. SIV clones encoding this Env variant mediated high levels of fusion, replicated efficiently in rhesus PBMC and macrophages, and induced multinucleated giant cell formation upon infection of macrophage cultures. We identified an N-linked glycosylation site, N173 in the V2 region, as a determinant of macrophage tropism. Loss of N173 enhanced SIVmac239 macrophage tropism, while restoration of N173 in SIVmac251 reduced macrophage tropism, but enhanced neutralization resistance to CD4/CCR5 binding site antibodies. SIVmac239 N173Q, which lacks the N173 glycosylation site, mediated CD4-independent fusion and cell-to-cell transmission with CCR5-expressing cells, but could not infect CD4-negative cells in single-round infections. Thus, CD4-independent phenotypes were detected only in the context of cell-cell contact. The N173Q mutation had no effect on SIVmac239 gp120 binding to CD4 in BIACORE and co-immunoprecipitation assays. These findings suggest that loss of the N173 glycosylation site increases SIVmac239 replication in macrophages by enhancing CD4-independent cell-to-cell transmission through CCR5-mediated fusion. This mechanism may facilitate escape of macrophage-tropic viruses from neutralizing antibodies, while promoting spreading infections by these viruses in vivo.

The HIV-1 envelope glycoprotein, Env, facilitates the translocation of the viral capsid across the cellular membrane. Env is a trimer of hetero-dimers composed of a gp120 subunit and gp41 transmembrane protein. The gp120 subunit binds the primary receptor, CD4, leading to conformational changes of Env that then promote binding to the coreceptor, principally CCR5 or CXCR4. As the sole protein on the surface of the virion, Env is under continuous pressure from the host's antibody response. Two classes of antibodies target the highly conserved receptor-binding sites of gp120: CD4-binding site (CD4bs) and CD4-induced (CD4i) antibodies.

Une des caractéristiques du Virus de l’Immunodéficience Humaine de type 1 (VIH-1) est sa diversification génétique extensive, qui lui permet d’échapper au système immunitaire. Néanmoins, il est nécessaire que le taux de mutation requis pour à cette évolution rapide ne compromette pas la fonctionnalité de ses protéines. Les travaux présentés ici ont eu pour objectif l’étude des réseaux de coévolution qui composent les glycoprotéines d’enveloppe (Env) afin de comprendre les règles qui sous-tendent leur évolution. Il a été mis en évidence que les régions variables de ces protéines, grâce à leur flexibilité structurelle, peuvent aussi servir à faciliter l’incorporation de mutations touchant les régions plus constantes. De plus, un réseau de coévolution impliqué dans les changements de conformations nécessaires à l’activité de Env a été identifié, soutenant le fait que ces régions variables ont un rôle central dans ces changements. Ces études démontrent le rôle crucial joué par les régions variables en dévoilant un nouvel aspect de leur contribution à l’évolution du VIH-1. / The Human Immunodeficiency Virus type 1 (HIV-1) is characterized by an extensive genetic diversification of its strains that allows the virus to escape the immune system. However, the mutation rate needed for this rapid evolution must not compromise the functionality of the viral proteins. The aim of the work presented here has been to study the coevolution networks that constitute the envelope glycoproteins (Env) in order to understand the rules driving their evolution. The results have highlighted that variable regions, thanks to their structural freedom, can facilitate the incorporation of mutations in more constant regions. Moreover, a coevolution network involved in the conformational changes required for the activity of Env has been identified, underlining the central role played by variable regions in these processes. Besides underscoring the crucial role played by variable regions in the functionality of Env, these studies unveil a new aspect of their contribution to HIV-1 evolution.

Lors de la transmission sexuelle du VIH-1, un seul ou un nombre très limité de variants viraux sont transmis parmi ceux présents chez le donneur. Il est important de comprendre si le variant transmis est sélectionné aléatoirement parmi ceux présents chez le donneur ou s’il possède un avantage sélectif qui le prédispose à établir plus efficacement une nouvelle infection. Lors de nos différents travaux, nous avons pu observer chez quatre patients une évolution parallèle des propriétés génétiques, antigéniques et fonctionnelles de la glycoprotéine d’enveloppe au cours de l’infection. L’évolution de certaines propriétés est répercutée à l’échelle populationnelle. Néanmoins nous avons montré que malgré ces évolutions, les virus transmis au sein d’une même chaîne de transmission présentent des propriétés biologiques conservées. L’ensemble de nos résultats vont en faveur d’une sélection d’un variant viral avec des propriétés particulières lors de la transmission. De plus le variant transmis possède une région V3 particulièrement conservée associée à un tropisme CCR5, une sensibilité au Maraviroc et semble avoir besoin d’un taux élevé de CD4 à la surface de la cellule cible. / During HIV-1 sexual transmission, a single virus among the numerous viral variants present in the donor is transmitted most often. The key question is to understand if transmitted variants are randomly selected among variants from the donor or they have biological properties that predispose them to establish more efficiently a new infection. We observed a parallel evolution of genetic, antigenic and functional properties of the envelope glycoprotein in four patients during the infection. In addition, the evolution of some properties is also observed at the populational level. However, we showed that transmitted variants from a same transmission chain share similar biological properties. Together our results suggest that the transmission bottleneck is mainly non-stochastic and involves the selection viral variants harboring specific phenotypic properties. Despite transmitted variants have a conserved V3 region associated with a CCR5 tropism, sensitivity to Maraviroc and seem to require high level of CD4 to efficiently infect target cells.

Spumaretroviren, oder Foamyviren (FV), unterscheiden sich von Orthoretroviren durch mehrere Besonderheiten in ihrer Replikationsstrategie. Das Partikel-assoziierte Hüllglykoprotein (Env-Protein) des „Prototype Foamy Virus“ (PFV) ist im Vergleich zu anderen retroviralen Hüllglykoproteinen einzigartig. Die Koexpression des PFV Env-Proteins für die PFV-Partikelfreisetzung ist essenziell und die spezifische Funktion kann nicht von heterologen viralen Env-Proteinen übernommen werden. Das Env-Protein des PFV durchläuft eine für ein Membranglykoprotein ungewöhnliche Biosynthese. Das Env-Vorläuferprotein besitzt zu Beginn eine Typ-III-Membrantopologie, bei der der N- und der C-Terminus im Zytoplasma lokalisiert sind. Während des Transports zur Zelloberfläche wird es posttranslational durch bisher unbekannte zelluläre Proteasen in mindestens drei Untereinheiten gespalten. Das N-terminale Signalpeptid bzw. Leader-Peptid (LP) hat eine Typ-II-Membrantopologie, mit dem N-Terminus im Zytoplasma und dem C-Terminus im Lumen, wohingegen die Transmembran (TM)-Untereinheit eine Typ-IMembrantopologie besitzt, bei der der N-Terminus im Lumen und der C-Terminus im Zytoplasma lokalisiert sind. Die interne Oberflächen (SU)-Untereinheit assoziiert vermutlich im Lumen mit der extrazellulären Domäne der TM-Untereinheit. Im Rahmen dieser Arbeit wurde der Beweis erbracht, dass Furin oder Furin-ähnliche Proteasen und nicht der Signalpeptidase-Komplex für beide proteolytischen Spaltungen verantwortlich sind. Durch die N-terminale Sequenzierung der SU- und der TM-Untereinheit eines aufgereinigten PFV Env-Immunoadhäsionsproteins wurden N-terminal von beiden Spaltstellen Furin- Konsensussequenzen identifiziert. Mutationsanalysen von zwei sich in diesem Bereich überlappenden minimalen Furin-Konsensussequenzen an der PFV LP/SU-Spaltstelle im wildtypischen PFV Env-Protein bestätigten die Ergebnisse der N-terminalen Sequenzierung und bewiesen, dass nur die erste Spaltstelle genutzt wird. Obwohl diese Mutanten aufgrund geringerer Partikelfreisetzung einen signifikanten Verlust der Infektiosität zeigten, wurde keine Korrelation zur Inhibierung der Spaltung beobachtet, da andere Mutanten mit normaler LP/SU-Spaltung einen ähnlichen Defekt besaßen. Virale Env-Proteine initiieren den Eintritt membranumhüllter Viren in die Wirtszelle durch die Bindung an zelluläre Rezeptoren. Dabei führen Konformationsänderungen in den Env- Proteinen zum Verschmelzen der Virusmembran mit der Zellmembran und weiterhin zur Aufnahme des Kapsids in das Zytoplasma der Wirtszelle. Die foamyviralen Env-Proteine sind in dieser Hinsicht keine Ausnahme und vermitteln die Anheftung an die Wirtszelle durch die Bindung an den bisher unbekannten zellulären Rezeptor. Der zelluläre foamyvirale Rezeptor ist vermutlich ein ubiquitäres Molekül, denn bisher konnte keine Zelllinie identifiziert werden, die gegen FV-Infektionen resistent ist. Bislang existieren nur sehr wenig strukturelle und funktionelle Informationen der extrazellulären Domänen des PFV Env-Proteins. Deshalb wurde im Hauptteil dieser Arbeit die PFV Env-Rezeptorbindungsdomäne (RBD) charakterisiert. Hierfür wurden rekombinante PFV Env-Immunoadhäsionsproteine verwendet und deren Bindungskapazitäten an Zielzellen in der durchflusszytometrischen Analyse bestimmt. Untersuchungen zeigten, dass sowohl die extrazelluläre Domäne der C-terminalen TM-Untereinheit als auch der Transport der Immunoadhäsionsproteine durch das spezifische PFV Env LP zum sekretorischen Weg für die Bindung an Zielzellen entbehrlich sind und ließen vermuten, dass die PFV Env-RBD innerhalb der SU-Untereinheit lokalisiert ist. N- und C-terminale Deletionsanalysen der PFV Env SU-Untereinheit enthüllten eine minimale kontinuierliche RBD von AS 225 bis 555. Interne Deletionen im PFV Env-Protein von AS 397 bis 483 wurden im Gegensatz zu deletierten Regionen von AS 262 bis 300 und AS 342 bis 396 ohne signifikanten Einfluss auf die Wirtszellbindung in Immunoadhäsionsproteinen toleriert. Die Analyse der Immunoadhäsionsproteine mit einzelnen substituierten Cysteinen in der PFV Env SU-Untereinheit zeigten, dass nur die Immunoadhäsionsproteine, die in der nicht essenziellen Region von AS 397 bis 483 lokalisierte Cysteine ersetzt hatten, eine Restbindungskapazität behielten. Interessanterweise zeigte die Analyse von verschiedenen N-Glykosylierungsmutanten eine bedeutende Rolle der Kohlenhydratkette an Position N391 im PFV Env-Protein entweder hinsichtlich der direkten Interaktion mit dem zellulären Rezeptor oder für die korrekte Faltung der PFV Env-RBD. Diese Ergebnisse weisen darauf hin, dass ein diskontinuierliches Sequenzmotiv von AS 225 bis 396 und AS 484 bis 555 für die Bildung der PFV Env-RBD essenziell ist und die darin lokalisierte potenzielle achte N-Glykosylierungsstelle eine entscheidende Rolle bei der Wirtszellbindung spielt. / Spumaretroviruses or foamy viruses (FVs) use a replication pathway with features distinctive from orthoretroviruses. The particle-associated envelope (Env) glycoprotein of prototype foamy virus (PFV) is unique compared to other retroviral envelope proteins since its coexpression is strictly required for the FV particle release process and its function cannot be replaced by heterologous viral glycoproteins. The PFV Env glycoprotein shows a highly unusual biosynthesis. Its precursor protein has a type III membrane topology with both the N-and C-terminus located in the cytoplasm. During its transport to the cell surface, it is posttranslationally processed by yet-unidentified cellular proteases into at least three subunits. The N-terminal signal or leader peptide (LP) has a type II membrane topology, whereas the C-terminal transmembrane (TM) subunit has a type I membrane topology. The internal surface (SU) subunit presumably associates with extracellular domains of TM on the luminal side. Here we provide strong evidence that furin itself or furin-like proteases and not the signal peptidase complex are responsible for both processing events. N-terminal protein sequencing of the SU and TM subunits of purified PFV Env-immunoglobulin immunoadhesin identified furin consensus sequences upstream of both cleavage sites. Mutagenesis analysis of two overlapping minimal furin consensus sequences at the PFV LP/SU cleavage site in the wild-type protein confirmed the sequencing data and demonstrated utilization of only the first site. Although these mutants displayed a significant loss in infectivity as a result of reduced particle release, no correlation to processing inhibition was observed, since another mutant having normal LP/SU processing had a similar defect. Viral Env proteins initiate entry of membrane enveloped viruses into cells by binding to cell surface receptors followed by conformational changes leading to membrane fusion and delivery of the genome containing viral capsid to the cytoplasm. The Env glycoproteins of FVs are no exception and mediate attachment to host cells through binding to an yet unknown ubiquitous cellular receptor molecule because no cell type is currently known that is resistant to FV entry. Little structural and functional information on the extracellular domains of PFV Env is available. In this study we characterized the PFV Env receptor-binding-domain (RBD) by flow-cytometric analysis of recombinant PFV Env immunoadhesin binding to target cells. Analysis showed that the extracellular domains of the C-terminal TM subunit as well as targeting of the recombinant immunoadhesins by the cognate LP to the secretory pathway were dispensable for target cell binding suggesting that the PFV Env RBD is contained within the SU subunit. N- and C- terminal deletion analysis of the SU domain revealed an minimal continuous RBD spanning aa 225-555, however internal deletions covering the region from aa 397-483, but not aa 262-300 or aa 342-396, were tolerated without significant influence on host cell binding. Analysis of individual cysteine point mutants in PFV Env SU revealed that only most of those located in the non-essential region from aa 397-483 retained residual binding activity. Interestingly, analysis of various N-glycosylation site mutants suggests an important role of the carbohydrate chain attached to N391 either for direct interaction with the cellular receptor or for correct folding of the PFV Env RBD. Taken together these results suggest that a bipartite sequence motif spanning aa 225-396 and aa 484-555 is essential for formation of the PFV Env RBD, with N-glycosylation site 8 playing a crucial role for host cell binding.

Lors de la primo-infection, la plupart des patients infectés par le VIH-1 développent des anticorps neutralisants autologues dirigés contre la glycoprotéine d’enveloppe virale. Ces anticorps exercent une pression de sélection conduisant à l’apparition de variants d’échappement. Nous avons montré que cette pression de sélection se répercute à l’échelle populationnelle, le VIH-1 en tant qu’espèce s’étant adapté au cours de l’épidémie à la réponse immunitaire de la population humaine en devenant de moins en moins sensible aux anticorps neutralisants. Cette adaptation du VIH‐1 a un impact sur les propriétés fonctionnelles de l’enveloppe. Nous avons ainsi observé une augmentation de l’infectivité associée à une augmentation de la cinétique d’entrée des virus qui circulent actuellement. Les virus contemporains montrent également une plus grande résistance à l’enfuvirtide, un inhibiteur de fusion, associée à une meilleure utilisation du co-récepteur CCR5 ainsi qu’une résistance accrue à l’inhibiteur du CD4 M48U1. L’ensemble de nos résultats est en faveur d’une adaptation progressive de l’espèce virale du VIH-1 à son hôte au cours de l’épidémie. / Most of HIV-1 infected patients develop autologous neutralizing antibodies against the viral envelope glycoprotein during primary infection. These antibodies exert a selective pressure that leads to the selection of escape variants. We showed that HIV-1 evolved at the population level towards an enhanced resistance to antibody neutralization over the course of the epidemic, subsequently to the selective pressure exerted by the individual autologous neutralizing antibodies responses. This antigenic drift has an impact on the functional properties of the viral envelope. We showed an increasing infectivity associated with an increasing entry kinetic of the most recently transmitted viruses. The contemporary viruses are also more resistant to the inhibitor of fusion enfuvirtide, related to a better use of the CCR5 co-receptor as well as a progressive increasing resistance to the CD4 inhibitor M48U1. Together our results are in favor of a progressive adaptation of HIV-1 species to humans over the course of the epidemic.

La problématique de la neutralisation par les anticorps constitue un enjeu majeur dans la perspective de la conception d’un vaccin efficace contre le VIH et les connaissances récemment acquises conforte NT l’absolue nécessité de maintenir une recherche cognitive fondamentale sur le sujet. L’un des objectifs de ce travail de thèse a été de documenter les propriétés biologiques en terme de sensibilité à la neutralisation de variants présents chez certains patients asymptomatiques à long terme (ALT) et présentant des caractéristiques particulières. Nous avons pu identifié certains déterminants moléculaires associés à la sensibilité ou à la résistance à l’anticorps monoclonal 2G12 tels le site potentiel de glycosylation (PNGS) en position N302 et la longueur de la boucle V1V2 du gène env. Nous avons ensuite caractérisé la relation entre l’évolution du gène env et la sensibilité à la neutralisation dans un contexte d’évolution tardive chez un patient ALT. Ces travaux ont permis de mettre en évidence une poursuite de l’évolution du gène env plus de 10 ans après l’infection et ceci malgré la présence d’anticorps largement neutralisants et d’une réponse autologue croissante au cours du temps. Le contexte de la transmission mère enfant (TME) constitue un modèle de choix afin d’étudier le rôle des anticorps neutralisants. Afin d’identifier d’éventuels corrélats de protection, mon travail a consisté à étudier la réponse neutralisante dans une population de 114 couples mères-enfants. Nous avons pu confirmer que le spectre de neutralisation des sérums maternels n’était pas associé à une moindre TME du VIH-1, mais que les anticorps neutralisant certains isolats pourraient constituer des indicateurs d’intérêt associé à un moindre risque de transmission. L’ensemble de ces travaux souligne à nouveau la complexité et la pertinence à poursuivre les investigations relatives à l’identification d’éventuels corrélats de protection. / Basic research on neutralizing antibodies. still remains relevant in term of HIV vacccine development. One of the aim of this thesis was to document the neutralization sensitivity of particular HIV-1variants from long term non progressor (LTNP) patients. We first identified molecular signatures associated with sensitivity to 2G12, such as a potential N-linked glycosylation site (PNGS) at N302 and a longer V1V2 loop of gp120. We also studied the relationship between long-term evolution of the virus and neutralization sensitivity in a LTNP patient. We showed that HIV-1 may continue to evolve in presence of both broadly neutralizing antibodies and increasing autologous neutralizing activity more than 10 years post-infection. Mother-to-child transmission provides a natural model for studying the role of neutralizing antibodies. In previous studies, we showed that the presence or high titers of neutralizing antibodies against a CRF01_AE strain, MBA, was associated with a lower rate of HIV-1 intrapartum transmission in Thailand (Barin et al., 2006; Samleerat et al., 2009). In order to confirm this observation and to identify potential correlates of protection in the MTCT context, we examined the breadth and levels of neutralizing antibodies in 57 transmitting and 57 non-transmitting untreated HIV-1 infected mothers. Our study confirmed that the breadth of maternal neutralizing antibodies was not associated with protection of infants from infection, but that neutralizing antibodies to particular strains might be associated with a lower rate of MTCT of HIV-1.

Le virus de l’hépatite C (VHC) est l’une des causes majeures de cirrhose du foie et de carcinome hépatocellulaire. Au courant de la première partie de ma thèse, nous nous sommes intéressés à caractériser plus en détail le rôle de SR-BI dans l’infection par le VHC. Bien que les mécanismes impliquant SR-BI dans la liaison du virus à l’hépatocyte aient été partiellement caractérisés, le rôle de SR-BI dans les étapes suivant la liaison du VHC reste encore largement méconnu. Afin de mieux caractériser le rôle de l’interaction VHC/SR-BI dans l’infection par le VHC, notre laboratoire à généré une nouvelle classe d’anticorps monoclonaux anti-SR-BI inhibant l’infection virale. Nous avons pu démontrer que SR-BI humain jouait un rôle dans le processus d’entrée du virus à la fois lorsde l’étape de liaison du virus à la cellule hôte mais aussi au cours d’étapes suivant cette liaison. Ainsi il serait intéressant de cibler cette fonction de SR-BI dans le cadre d’une stratégie antivirale pour lutter contre l’infection parle VHC. Dans la seconde partie de ma thèse, nous avions pour but de caractériser les mécanismes moléculaires intervenant dans la réinfection du greffon lors de la transplantation hépatique (TH). Nous avons ainsi identifiés 3 mutations adaptatives dans la glycoprotéine d’enveloppe E2 responsables de l’entrée virale augmentée du variant hautement infectieux. Ces mutations influent sur la dépendance au récepteur CD81 du VHC résultant en une entrée virale accrue. L’identification de ces mécanismes va nous permettre une meilleure compréhension de la pathogénèse de l’infection par le VHC, et est un premier pas pour le développement d’une stratégie préventive antivirale ou vaccinale. / Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma. In the first part of my PhD, we aimed to further characterize the role of scavenger receptor class B type I (SR-BI) in HCV infection. While the SR-BI determinants involved in HCV binding have been partially characterized, the post-binding function of SR-BI remains remained largely unknown. To further explore the role of HCV-SR-BI interaction during HCV infection, we generated a novel class of anti-SR-BI monoclonal antibodies inhibiting HCV infection. We demonstrated that human SR-BI plays a dual role in the HCV entry process during both binding and post-binding steps. Targeting the post-binding function of SR-BI thus represents an interesting antiviral strategy against HCV infection. In the second part of my PhD, we aimed to characterize the molecular mechanisms underlying HCV re-infection of the graft after liver transplantation (LT). We identified threeadaptive mutations in envelope glycoprotein E2 mediating enhanced entry and evasion of a highly infectious escape variant. These mutations markedly modulated CD81 receptor dependency resulting in enhanced viral entry. The identification of these mechanisms advances our understanding of the pathogenesis of HCV infection and paves the way for the development of novel antiviral strategies and vaccines.